logo-loader
RNS
ConvaTec Group PLC

Convatec 10-month trading update

RNS Number : 5762D
Convatec Group PLC
18 November 2026
 


Trading update for the ten months ended 31 October 2026                     18 November 2026

 

Growth accelerating in the second half

 

 

Key points

 

  • YTD organic revenue growth[1] ex-InnovaMatrix of 6.6%[2]. YTD organic growth including InnovaMatrix of 3.7%; reported growth 4.8%3

 

  • Stronger H2 growth in Infusion Care and Continence Care

 

  • Upgrading FY26 Group revenue growth expectations to 6.25-7.0% (previously 5.5-6.5%)

 

Accelerating organic revenue growth; increased FY26 guidance for CC and IC

 

  • Advanced Wound Care (AWC) was low-to-mid single digit ex-InnovaMatrix YTD, similar to H1. ConvaFoam continued to gain share and Aquacel AG+ Extra grew slightly ahead of soft markets
    • We continue to expect mid-single digit growth ex-InnovaMatrix in FY26
    • InnovaMatrix: we now expect FY26 revenue of c.$5m (previously $5-10m)

 

  • Ostomy Care (OC) was mid-single digit YTD, similar to H1. Our 1-piece soft convex product, Esteem Body, continued to gain share
    • Our 2-piece soft convex product, Natura Body, is on track to launch in mid-2027
    • We continue to expect mid-single digit OC growth in FY26

 

  • Continence Care (CC) accelerated to mid-to-high single digit growth YTD, from increased US new patient volumes and further strong growth outside the US, each supported by excellent customer service. Our compact catheter, GentleCath Air for Women, continued to gain share
    • Cure Aqua began launching in September; GentleCath Air Pocket and Set in November
    • We now expect mid-to-high single digit CC growth in FY26 (previously MSD)

 

  • Infusion Care (IC) accelerated to double-digit growth YTD, driven by faster H2 diabetes growth and continued strong growth in AbbVie’s treatment of Parkinson’s disease
    • Improved execution delivered increased manufacturing volumes
    • We now expect double-digit IC growth in FY26 (previously HSD)

 

FY26 Group guidance and medium-term financial targets

 

  • Group organic revenue growth1 ex-InnovaMatrix 6.25-7.0%

 

  • Adjusted operating profit margin of at least 23% (unchanged). This includes c.65 bps adverse FY26 FX headwinds and c.90 bps InnovaMatrix headwind

 

  • Double-digit growth in adjusted EPS (unchanged)

 

  • Reiterating our medium-term targets: 6-8% organic revenue and double-digit adjusted EPS growth; reaching mid-20s% adjusted operating margin from 2027

 

 

Jonny Mason, Chief Executive Officer, commented:

 

“Revenue growth has accelerated in the second half, as we expected. We saw notable strength in Infusion Care, where improved execution enabled us to meet rising demand, ahead of new capacity coming online in 2027. Overall, we continued to gain share in all categories, underpinned by new product launches.

 

“We are making good progress executing our Accelerate strategy, the next exciting chapter of Convatec’s story. We are investing to accelerate growth, supporting our new product launches which are winning share with healthcare professionals and users. We are improving execution and are positioned to deliver sustainable 6-8% revenue growth and double-digit annual EPS growth, supporting more people around the world with innovative, trusted medical solutions for chronic conditions.”

 

Other FY26 guidance

 

  • Total capex at the upper end of $200-230m range. Within this, growth capex at the upper end of $135-165m range as we accelerate expanding capacity
  • $200m share buyback on track to complete in FY26
  • Adjusted net finance expense of c.$75m (previously $70-75m)
  • Adjusted book tax rate of c.23% (unchanged); cash tax increasing c.400bps YoY to c.16%
  • Cash costs of adjusting items of c.$30m (previously $20m)
  • c.90% equity cash conversion (previously c.100%), with strong working capital inflow in H2 partly offset by increases in cash tax and adjusting items

 

Foreign exchange and macroeconomic environment

 

  • If current spot rates hold for the remainder of FY26, the estimated tailwind to FY26 revenue growth will be c.90 bps (previously 130 bps) and the headwind to operating margin will be c.65 bps (previously 40 bps)

 

Launches, innovation and pipeline

 

  • AWC: our early phase ConvaNiox European launch continues to receive excellent user feedback. Reimbursement is now available in the UK community setting via NHS drug tariff. Recruitment in our US diabetic foot ulcer randomised controlled trial is now complete (300 patients), with results expected in 2027, while the US De Novo submission is ongoing. Indication expansion has been submitted in Europe, and our commercial footprint has extended to Australia. ConvaVAC and ConvaFiber are on limited European release, with US full launch expected in 2027
  • OC: Esteem Body growth remains ahead of expectations, with segment share now up to c.15%; our two-piece equivalent Natura Body is on track to launch in mid-2027. This will remove a gap for soft convex products in our portfolio, essential for growth in the US  
  • CC: GentleCath Air for Women continued to win share in compact catheters in the US and Europe. Cure Aqua, our new ready-to-use hydrophilic catheter, started launching in September and GentleCath Air Pocket & Set, our compact male and unisex catheter, in November, completing a gap for compact, ready-to-use hydrophilic catheters in our portfolio
  • IC: our Inset Guard platform technology in diabetes is broadening the form factors we serve, with more and varied pump types including our first hybrid patch pump (announced in May 2026). We are also supporting additional new advanced Parkinson's disease therapies

 

 

Conference call details

 

Jonny Mason, Chief Executive Officer, and Fiona Ryder, Chief Financial Officer, will host a conference call for analysts and investors to discuss the trading update at 8:30am (UK time) on 18 November 2026. To access the live webcast, please register here.

 

To ask questions and join by conference call, please register here to receive dial-in details.

 

 

Contacts 

Analysts & Investors

David Philips

Vice President, Head of Investor Relations

+44 (0) 7909 324994

ir@convatec.com

 

 

 

 

Delene Cole

 

 

Investor Relations Manager

 

 

 

 

Media

FGS Global

Convatec-UK@fgsglobal.com

 

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com.

 

All product and programme names are trademarks of Convatec and its subsidiaries, including: InnovaMatrix®, ConvaFoam™, ConvaNiox™, Aquacel®, Aquacel™ ConvaFiber™, ConvaVAC™, Esteem Body™, Esenta™, Natura® Body, Flexi-Seal™ Air, Cure™ Aqua, GentleCath Air™ for Women, GentleCath Air™ for Men, GentleCath Air Pocket™, GentleCath Air Set™, Neria™ Guard, Inset™ Guard and me+ programme.

 

Forward Looking Statements

This document includes certain forward-looking statements with respect to the operations, performance and financial condition of the Group. Forward-looking statements are generally identified by the use of terms such as “believes”, “estimates”, “aims”, “anticipates”, “expects”, “intends”, “plans”, “predicts”, “may”, “will”, “could”, “targets”, “continues”, or their negatives or other similar expressions. These forward-looking statements include all matters that are not historical facts.

 

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic and competitive uncertainties and contingencies that are difficult to predict and many of which are outside the Group’s control. As such, no assurance can be given that such future results, including guidance provided by the Group, will be achieved. Forward-looking statements are not guarantees of future performance and such uncertainties and contingencies, including the factors set out in the “Principal Risks” section of the Strategic Report in our Annual Report and Accounts, could cause the actual results of operations, financial condition and liquidity, and the development of the industry in which the Group operates, to differ materially from the position expressed or implied in the forward-looking statements set out in this document. Past performance of the Group cannot be relied on as a guide to future performance.

 

Forward-looking statements are based only on knowledge and information available to the Group at the date of preparation of this document and speak only as at the date of this document. The Group and its directors, officers, employees, agents, affiliates and advisers expressly disclaim any obligations to update any forward-looking statements (except to the extent required by applicable law or regulation). LEI number - 213800LS272L4FIDOH92

 

 


[1] Organic revenue growth is calculated by applying the applicable prior period average exchange rates to the Group's actual performance in the respective period and excluding acquisitions and divestitures.

[2] In the ten months to 31 Oct 2026, non-InnovaMatrix revenue represented over 99.5% of Group revenues.

3 US dollar depreciation YoY drove c.1.1% FX revenue translation benefit YTD.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBRBLTMTJBBIF
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Holding(s) in Company

1 day, 10 hours ago

Transaction in Own Shares

3 days, 10 hours ago

Transaction in Own Shares

1 week, 3 days ago

Director updates

2 weeks, 2 days ago

Total Voting Rights

2 weeks, 3 days ago

Transaction in Own Shares

2 weeks, 3 days ago

Holding(s) in Company

on 10/20/2026

8 min read